<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006864</url>
  </required_header>
  <id_info>
    <org_study_id>CHIR1899</org_study_id>
    <secondary_id>CWRU-CHIR-1899</secondary_id>
    <secondary_id>CHIR-MA-99-01</secondary_id>
    <secondary_id>CWRU-010002</secondary_id>
    <secondary_id>NCI-G00-1875</secondary_id>
    <nct_id>NCT00006864</nct_id>
  </id_info>
  <brief_title>Interleukin-2 in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiron Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who&#xD;
      have metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall response rate, complete and partial response rates, and duration&#xD;
           of response in patients with metastatic renal cell carcinoma treated with low-dose&#xD;
           interleukin-2.&#xD;
&#xD;
        -  Determine the overall survival, one-year progression-free survival, and two-year&#xD;
           progression-free survival in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of adverse events in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive low-dose interleukin-2 subcutaneously 5 days a week for 6 weeks. Courses&#xD;
      repeat every 9 weeks for at least 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 464 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic renal cell carcinoma&#xD;
&#xD;
               -  Clear cell&#xD;
&#xD;
               -  Papillary&#xD;
&#xD;
               -  Sarcomatoid&#xD;
&#xD;
               -  Mixed&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Evidence of disease following surgical resection of metastases&#xD;
&#xD;
          -  No CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  WBC at least 4,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception (barrier plus 1 other method)&#xD;
&#xD;
          -  Thyroid-stimulating hormone normal&#xD;
&#xD;
          -  No known hypersensitivity or allergy to components of recombinant human interleukin-2&#xD;
&#xD;
          -  No known autoimmune disease (e.g., Crohn's disease)&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior recombinant human interleukin-2&#xD;
&#xD;
          -  No concurrent interferon alfa&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent cytoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy (e.g., medroxyprogesterone) other than estrogen&#xD;
             replacement therapy&#xD;
&#xD;
          -  No concurrent prophylactic glucocorticoids (replacement doses and topical use allowed)&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to index lesion&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior surgery for renal cell carcinoma allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior systemic therapy for renal cell carcinoma&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs or participation in another clinical study&#xD;
&#xD;
          -  No concurrent iodinated radiocontrast dye&#xD;
&#xD;
          -  No concurrent drugs for another indication that has purported activity in treatment of&#xD;
             neoplasia (e.g., thalidomide)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Connell, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Seidman Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Connecticut Oncology-Hematology Associates</name>
      <address>
        <city>Torrington</city>
        <state>Connecticut</state>
        <zip>06790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>May 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2003</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

